High Yield of Pleural Cell-Free DNA for Diagnosis of Oncogenic Mutations in Lung Adenocarcinoma

Abstract

Pleural cytology is currently used to assess targetable mutations in patients with advanced lung adenocarcinoma. However, it is fraught with low diagnostic yield. Can pleural cell-free DNA (cfDNA) be used to assess targetable mutations in lung adenocarcinoma patients with malignant pleural effusions (MPE)? Patients with lung adenocarcinoma MPE were recruited prospectively between January 2017 and September 2021. Oncogenic mutations were assessed by treating providers using pleural fluid cytology or lung cancer biopsies. Pleural and plasma cfDNA were used to assess the mutations using next generation sequencing (NGS). Fifty-four pleural fluid samples were collected from 42 patients. The diagnostic yield to detect oncogenic mutations for pleural cfDNA, pleural cytology, biopsy and plasma cfDNA was 49/54 (90.7%), 16/33 (48.5%), 22/25 (88%) and 24/32 (75%), respectively, P <0.001. The agreement of mutations in positive samples between pleural cfDNA and pleural cytology was 100% while the agreement of pleural cfDNA with biopsies was 89.4%. The median concentration (Q1-Q3) of pleural cfDNA was higher than plasma: 28,444 (4,957-67,051) vs. 2,966.5 (2,167-5,025) copies of amplifiable DNA per ml, P <0.01. Median of 5 ml (interquartile range, Q1-Q3, 4.5-5) of pleural fluid supernatant was adequate for cfDNA testing. The diagnostic yield of pleural cfDNA NGS for oncogenic mutations in lung adenocarcinoma patients is comparable to tumor biopsies and higher than pleural cytology and plasma cfDNA. The pleural cfDNA can be longitudinally collected, readily incorporated in clinical workflow and may decrease the need for additional biopsies.